Clinical Research

South Shore Neurologic Associates Clinical Research Department has focused on bringing groundbreaking medication opportunities to patients in need. The clinical trials are designed to help evaluate medications & devices prior to FDA approval, as well as further evaluate post-approval medications. Bringing high-tech research to our community provides opportunities that allow our patients access to medications & devices that are on the cutting edge of science opening new avenues for those who are unable to obtain relief from other therapies. We have participated in many clinical trials for Multiple Sclerosis, Parkinson's disease, Huntington's disease, and compassionate access treatments for ALS.

Medical Staff:

Lori Fafard, RN, BSN, CNRN, MSCN, CCRP
Laura Graffitti, RN, BSN, CNRN, MSCN, CCRP
Kim Higdon RN
Frances Lewandowski, Clinical Research Coordinator
Erin Vacey, Clinical Assistant

MONTHLY UPDATE ON CLINICAL TRIALS aS of 9/1/14 

Study Name

Study Coordinator(s)

Phone Extension

Study Population

Enrolling Y/N

ASSESS (CFTY720D2312) Site # 5046 Kim 2247
RRMS; new start Gilenya Y
AUSPEX Site #342 Laura, Kim, Lori 2207, 2247, 2205
HD; Xenazine new starts & switches that are currently on Xenazine Y
Chugai nmo/nmosd Kim 2247
NMO: Multi-center, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of SA237 as monotherapy in pt’s with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD)(can enroll up to 6 subjects) A1 – see attached y
CAMMS03409 site 1160 Lori
2205 RRMS: Campath
n
ENDORSE 109-MS-303 Laura
2207 RRMS: extension study BG12 (Tecfidera)
n
ESTEEM 109-MS-401 (ICF 7-17-14)
Laura
2207 RRMS; observation new start Tecfidera LT benefit; determine reasons for SAE’s, DMT’s routine prescription utilization & effectiveness
y
EXPAND (CBAF)
Kim
2247 SPMS – oral agent
y
Cidp (cfty72012201) lori 2205 CIDP subjects; 11-26-14 received major revision guidelines to eCRF re: completion of Liver Event eCRF pages.
y
MANAGE 109MS403 Laura 2207
RRMS observation new start Tecfidera Y
DIOGENIX Kim 2247
Waiting for closeout visit N
ESTEEM 109-MS-401 (ICF 7-17-14) Laura 2207
RRMS: observation new start Tecfidera LT benefit; determine reasons for SAE's DMT's routine prescription utilization and effectiveness Y
EXPAND (CBAF) Kim, Lori BU 2247, 2205
SPMS- Oral agent Y
PASSAGE (CFTY720D2403) Laura 2207
Observation study new starts ALL DMT's Y
PREFERMS (CFTY720DUS09) Laura, Kim, Lori 2207, 2247, 2205
RRMS N
PREIMERE (ORACLE) Laura 2207
Observation Study F/U N
PRISMS (AVANIR) Lori 2205
Pseudobulbar Affective Disorder Y
REDEFINE (EMR 200136-573) Fran 2206
Rebidose vs. Rebiject II Y
RESOUND (EMR 200136-586) TBA
Tecfidera to Rebif Y
RESPOND (109MS404) Laura 2207
12 Month Observational Tecfidera Y
ROCHE WA21093 Laura 2207
RRMS N
ROCHE WA25046 Laura 2207
RRMS N
STRATIFY 101JC402 Erin et al 2246
Tysabri JCV N
STRIVE (101MS407) Lori and Kim BU 2205, 2247
New Start Tysabri JCV (-) <3yrs Diagnosis Y
TRANSITION (CFTY720D2405) Laura 2207
Tysabri Gilenya Y
TYGRIS Lori 2205
New start Tysabri observational N
WILKENS Lori, Laura, Kim, Fran, Erin 2205, 2207, 2247, 2206, 2246
Neurotrax validation study MS pt's 95 subjects (15 of 95 normal controls) Y

Locations this service is offered at:

Patchogue
77 Medford Avenue (Route 112)
Patchogue, NY 11772

Tel: 631-758-1910
Fax: 631-750-1014